Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03101358 · ClinicalTrials.gov registry record · Phase 1
Study of Topical SOR007 Ointment for Cutaneous Metastases
A Phase 1 study, sponsored by NanOlogy.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03101358 is a Phase 1 study that has completed, run by NanOlogy. The registered enrollment target is 23 participants.
The verdict
NCT03101358, a Phase 1 study, has completed, sponsored by NanOlogy.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study evaluates a topical nanoparticle paclitaxel ointment (SOR007) for the treatment of cutaneous metastases from non-melanoma cancer in adults. Three concentrations of SOR007 will be evaluated in dose-rising cohorts of three. An expanded cohort will treat additional subjects at the maximum tolerated dose.
Interventions
- DRUG SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2020-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03101358
The ClinicalTrials.gov registry entry for NCT03101358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NanOlogy, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment is the first listed.
NCT03101358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03101358 about?
NCT03101358 is a clinical study titled "Study of Topical SOR007 Ointment for Cutaneous Metastases". This study evaluates a topical nanoparticle paclitaxel ointment (SOR007) for the treatment of cutaneous metastases from non-melanoma cancer in adults. Three concentrations of SOR007 will be evaluated in dose-rising cohorts of three. An expanded cohort will treat additional subjects at the maximum to...
What is the current status of trial NCT03101358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-01-31. Estimated completion is 2020-04-29.
What interventions are being tested in trial NCT03101358?
The interventions under investigation include: SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment (DRUG).
Who is sponsoring clinical trial NCT03101358?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.